Protein Kinase B/Akt Mediates Effects of Insulin on Hepatic Insulin-like Growth Factor-binding Protein-1 Gene Expression through a Conserved Insulin Response Sequence*

Stephen B. CichyDagger §, Shahab UddinDagger §, Alexey DanilkovichDagger §, Shaodong GuoDagger §, Anke Klippelpar , and Terry G. UntermanDagger §**

From the Dagger  Departments of Medicine and Physiology and Biophysics, University of Illinois College of Medicine at Chicago, Chicago, Illinois 60612, the § Veterans Affairs Chicago Health Care System, West Side Division, Chicago, Illinois 60612, and the par  Chiron Corporation, Emeryville, California 94608-2916

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References

Insulin regulates the expression of multiple hepatic genes through a conserved insulin response sequence (IRS) (CAAAAC/TAA) by an as yet undetermined mechanism. Protein kinase B/Akt (PKB/Akt), a member of the PKA/PKC serine/threonine kinase family, functions downstream from phosphatidylinositol 3'-kinase (PI3K) in mediating effects of insulin on glucose transport and glycogen synthesis. We asked whether PKB/Akt mediates sequence-specific effects of insulin on hepatic gene expression using the model of the insulin-like growth factor binding protein-1 (IGFBP-1) promoter. Insulin lowers IGFBP-1 mRNA levels, inhibits IGFBP-1 promoter activity, and activates PKB/Akt in HepG2 hepatoma cells through a PI3K-dependent, rapamycin-insensitive mechanism. Constitutively active PI3K and PKB/Akt are each sufficient to mediate effects of insulin on the IGFBP-1 promoter in a nonadditive fashion. Dominant negative K179 PKB/Akt disrupts the ability of insulin and PI3K to activate PKB/Akt and to inhibit promoter activity. The IGFBP-1 promoter contains two IRSs each of which is sufficient to mediate sequence-specific effects of insulin, PI3K, and PKB/Akt on promoter activity. Highly related IRSs from the phosphoenolpyruvate carboxykinase and apolipoprotein CIII genes also are effective in this setting. These results indicate that PKB/Akt functions downstream from PI3K in mediating sequence-specific effects of insulin on the expression of IGFBP-1 and perhaps multiple hepatic genes through a conserved IRS.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References

The binding of insulin to its cell surface receptor results in the activation of multiple signaling pathways (1). Phosphatidylinositol 3'-kinase (PI3K)1 plays an important role in mediating cellular effects of insulin (2, 3). Rapamycin-sensitive pathways mediate PI3K-dependent effects of insulin on p70S6 kinase activity and cellular proliferation (4) and hexokinase II expression (5). Protein kinase B/Akt (PKB/Akt), a PKA/PKC serine/threonine kinase family member (6), is activated through a PI3K-dependent mechanism that is not blocked by rapamycin (7) and mediates effects of growth factors on cell survival (8-10). PKB/Akt is thought to mediate the phosphorylation and inactivation of glycogen synthase kinase-3 by insulin (11) and stimulates glucose transporter translocation in 3T3-L1 adipocytes (12). The role of PKB/Akt in mediating sequence-specific effects of insulin on hepatic gene expression has not been determined.

Insulin regulates gene expression in a variety of tissues (13). Hepatic expression of insulin-like growth factor binding protein-1 (IGFBP-1) is rapidly suppressed by insulin at the level of gene transcription (14-16) through two insulin response sequences located ~100 bp 5' to the RNA cap site (17, 18). Each IRS is sufficient to mediate effects of insulin on promoter activity (18, 19) and closely resembles IRSs, which mediate effects of insulin on several other genes in the liver, including phosphoenolpyruvate carboxykinase (PEPCK) (20) and apolipoprotein CIII (apoCIII) (21). These observations have suggested that a common, but as yet undetermined mechanism may mediate the effects of insulin on multiple hepatic genes.

Recent studies with wortmannin, a PI3K inhibitor, indicate that PI3K is necessary for insulin to reduce IGFBP-1 and PEPCK mRNA levels in liver-derived cells stimulated with dexamethasone and either glucagon or 8-(4-chlorophenylthio)-cAMP, respectively (22, 23). Since multiple mechanisms involving distinct cis-acting DNA response sequences may mediate effects of insulin on gene expression in cAMP/glucocorticoid-stimulated cells (24, 25), we chose to examine mechanisms mediating the effects of insulin on IGFBP-1 expression under basal conditions where specific IRSs are known to be involved (18). To our knowledge, this study provides the first report that PKB/Akt is necessary and sufficient to regulate gene expression through a specific response sequence, and, in this case, mediates effects of insulin on basal hepatic gene expression through a conserved IRS.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References

cDNA Clones and Plasmid Expression Vectors-- The SauI-HgaI fragment of the IGFBP-1 promoter was inserted into the pGL2 polylinker (Promega) (BP1.luc), and an NheI site was created by site-directed mutagenesis of bp -112 and -113 (BP1.Nhe), as reported previously (18). The BamHI site in pGL2 was disrupted and the IGFBP-1 promoter containing the NheI site was subcloned into this vector. Using a unique BamHI site located 3' of IRSB in the IGFBP-1 promoter (Table I), we excised the NheI-BamHI fragment and replaced it with synthetic double-stranded oligonucleotides to create altered IRSs. All constructs were confirmed by dideoxy sequencing.

The cDNA clone of human IGFBP-1 was provided by D. Clemmons (26). The expression vector for dominant negative p85 (Delta p85) was provided by M. Kasuga (27). The hemagglutinin (HA)-tagged human PKB/Akt cDNA (provided by R. Roth) (28) was subcloned into pCDNA3. HA-tagged myristoylated PKB/Akt (Myr-PKB/Akt) and Myc-tagged K179 PKB/Akt expression vectors were provided by T. Franke (8). Expression vectors for dominant negative H-Ras (N17Ras), Raf (C4bRaf), mitogen-activated kinase kinase (MEKK1S222A), RhoA (N19RhoA), Rac (N17Rac), Cdc42 (N17Cdc42), SEK-1 (SEK1-K/R), and PKCzeta (zeta mut) were kindly provided by G. Cooper (29), U. Rapp (30), E. Krebs (31), J. Gutkind (32), L. Zon (33), and J. Moscat (34).

Cell Culture and Northern Blotting-- HepG2 cells were grown in 100-mm dishes to ~70% confluence in Opti-MEM plus 5% BCS, rinsed, and stabilized for 24 h in 10 ml of DMEM with 1 g/liter BSA. LY294002 (Calbiochem) and wortmannin and rapamycin (Sigma) were added in dimethyl-d6-sulfoxide (Me2SO) (0.125%, v/v) 30 min prior to addition of recombinant human insulin (Sigma). Wortmannin or Me2SO was added again 90 min later to maintain levels (22). Total cellular RNA was prepared with TRI-Reagent-LS per the manufacturer's instructions (Molecular Research) and 10 µg loaded for gel electrophoresis and transfer to Nytran membranes (Qiagen). Membranes were probed with IGFBP-1 and GAPDH cDNAs labeled with [alpha -P32]dATP (Amersham Pharmacia Biotech) by random priming and transcripts visualized by autoradiography and quantified by phosphorimaging.

Transient Transfection Assays-- HepG2 cells (1 × 106/60-mm dish) were plated in Opti-Mem/BCS and transfected with calcium phosphate precipitates including a cytomegalovirus-driven beta -galactosidase (beta -gal) expression vector, as before (35). Cells were rinsed, then refed with DMEM/BSA and appropriate supplements. Lysates were prepared 18 h later with lysis buffer (Promega). Luciferase activity was measured with an Optocomp-I luminometer (MGM Instruments) and results adjusted for beta -gal activity. Each experiment was performed in triplicate and repeated at least three times.

Immunoprecipitation, Western Blotting, and Kinase Assays-- Cell lysates were prepared in the presence of phosphatase and protease inhibitors (36) and cleared by centrifugation. Endogenous p70S6 kinase was precipitated with anti-p70 antiserum (Upstate Biotechnology, Inc.) and protein-G and kinase activity was measured as 32P labeling of synthetic substrate (AKRRRLSSLRA) in the presence of PKA, PKC, and calcium-dependent kinase inhibitors using the S6 kinase assay kit (Upstate Biotechnology, Inc.) according to the manufacturer's instructions. Substrate-bound radioactivity was collected by binding to p81 phosphocellulose discs and quantified by scintillation counting after rinsing with phosphoric acid.

Endogenous or HA-tagged PKB/Akt was immunoprecipitated with rabbit polyclonal anti-Akt (Santa Cruz) or mouse monoclonal anti-HA (12CA5) (Boehringer Mannheim), respectively. For Western blotting, immunoprecipitated proteins were separated by 8% reduced SDS/PAGE prior to transfer to nitrocellulose and analysis using the ECL kit (Amersham Pharmacia Biotech) with enhanced chemiluminescence. To measure kinase activity, immunoprecipitated PKB/Akt was reacted in kinase buffer containing [gamma -P32]ATP and histone 2B, as reported previously (36). 32P-Labeled protein was separated by 15% SDS-PAGE and detected by autoradiography, and the relative intensity of labeling was quantified by phosphorimaging.

    RESULTS AND DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References

As shown in Fig. 1A, insulin lowers IGFBP-1 mRNA levels in HepG2 cells by ~50%. Wortmannin, which directly inhibits the p110 catalytic subunit of PI3K, increases the level of IGFBP-1 mRNA and largely prevents the ability of insulin to lower IGFBP-1 mRNA levels. LY294002, another highly specific PI3K inhibitor that is structurally unrelated to wortmannin and more stable in solution, also increases IGFBP-1 mRNA levels and completely blocks the effect of insulin. In contrast, rapamycin reduces IGFBP-1 mRNA levels by ~20% and does not disrupt the ability of insulin to further lower mRNA levels. In vitro kinase assays confirm that this dose of rapamycin reduces basal p70S6 kinase activity and blocks its activation by insulin for up to 20 h in HepG2 cells (Fig. 1B). These results indicate that PI3K contributes negatively to the regulation of basal IGFBP-1 mRNA levels and that insulin lowers IGFBP-1 mRNA levels through a PI3K-dependent mechanism that is not sensitive to inhibition by rapamycin.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 1.   Effects of PI3K inhibitors and rapamycin. A, IGFBP-1 mRNA levels. HepG2 cells were stabilized in serum-free medium, then treated with 200 nM wortmannin (Wort), 50 µM LY294002 (LY), or 200 nM rapamycin (Rapa) 30 min prior to the addition of 100 nM insulin or buffer alone (control). RNA was extracted 4 h after the addition of insulin and prepared for Northern blotting with an IGFBP-1 cDNA probe. Membranes were reprobed for GAPDH mRNA. Transcripts were visualized by autoradiography and hybridization intensity quantified by phosphorimaging. IGFBP-1 mRNA levels are adjusted for GAPDH and expressed relative to control. The mean and S.E. for a representative experiment performed in triplicate is shown. B, p70S6 kinase activity. HepG2 cells were stabilized in serum-free medium for 18 h, then treated with 200 nM rapamycin for 0, 4, or 20 h prior to the addition of 100 nM insulin. Lysates were prepared 10 min after the addition of insulin, and p70S6 kinase activity was measured after immunoprecipitation as the incorporation of 32P into a synthetic peptide, as described under "Materials and Methods." C, IGFBP-1 promoter activity. HepG2 cells were transfected with 10 µg of plasmid DNA, including 3 µg of BP1.luc reporter gene plasmid, 2 µg of beta -gal vector, and 5 µg of the Delta p85 expression vector or empty vector. Cells were treated with 50 µM LY294002 (LY), 200 nM rapamycin (Rapa), or Me2SO for 30 min prior to the addition of 100 nM insulin or buffer alone (control). Cell lysates were prepared 18 h later. Luciferase activity is adjusted for beta -gal and expressed relative to control.

We next asked whether PI3K is required for insulin to inhibit IGFBP-1 promoter activity. As shown in Fig. 1B, insulin inhibits IGFBP-1 promoter activity by ~50% in HepG2 cells, consistent with results obtained at the mRNA level. LY294002, which directly inhibits the activity of the p110 catalytic subunit of PI3K, increases IGFBP-1 promoter activity and prevents the inhibitory effect of insulin. Co-transfection with a dominant negative form of the 85-kDa regulatory subunit of PI3K (Delta p85) (27), which blocks the activation of PI3K by insulin without disrupting intrinsic p110 activity, also completely disrupts the inhibitory effect of insulin but without altering basal promoter activity. In contrast, treatment with rapamycin lowers basal promoter activity by ~20% and does not disrupt the inhibitory effect of insulin, consistent with results obtained at the mRNA level. These results indicate that PI3K contributes negatively to the regulation of basal IGFBP-1 promoter activity, and that insulin inhibits promoter activity through a PI3K-dependent mechanism that is not blocked by rapamycin.

To determine whether PI3K is sufficient to mediate the effect of insulin on promoter activity, we next performed studies with constitutively active forms of the 110-kDa catalytic subunit of PI3K created by joining the catalytic (p110) and regulatory (p85) subunits through a hinge peptide (p110*) (36) or by adding the Src myristoylation sequence to p110 (Myr-p110), as described previously (37). As shown in Fig. 2A, expression of increasing amounts of either p110* or Myr-p110 inhibits IGFBP-1 promoter activity in a dose-dependent fashion. There is no additive effect of insulin on promoter activity in cells transfected with either p110* or Myr-p110, indicating that PI3K is sufficient to mediate the full effect of insulin on basal IGFBP-1 promoter activity.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of constitutively active PI3K on promoter activity. A, expression of constitutively active PI3K. HepG2 cells were transfected with a total of 10 µg of DNA/dish, including 3 µg of BP1.luc reporter gene construct, 2 µg of beta -gal vector, and 0, 0.1, 0.3, or 1 µg of p110* or Myr-p110 plus 4-5 µg of empty vector. To examine for additive effects, cells were transfected with precipitates containing 1 µg p110* or Myr-p110 vector and treated with 100 nM insulin or buffer alone. B, effect of dominant negative forms of potential downstream effectors. Cells were transfected with 15 µg of DNA/dish, including 2 µg of BP1.luc, 2 µg of beta -gal, 1 µg of p110* or empty vector (control), and 10 µg of vectors expressing dominant negative forms of Ras (N17Ras), Raf (C4bRaf), MEKK1 (S222A), Rho (N19RhoA), Rac (N17Rac), Cdc42 (N17Cdc42), SEKI (SEK1-K/R), or zeta PKC (PKCzeta mut), then stabilized in DMEM/BSA for 18 h before harvest and analysis of luciferase activity.

Multiple effectors have been implicated in mediating downstream defects of PI3K in addition to p70S6 kinase, including the Ras-Raf-MEKK1-MAPK pathway (36, 38), Rho-related small GTP-binding proteins (Rho, Rac, and Cdc42) (39), protein kinase Czeta (40), the SEK1/jun kinase pathway (37) and PKB/Akt (7, 37). As shown in Fig. 2B, co-transfection with dominant negative forms of Ras (N17Ras), Raf (C4bRaf), MEKK1 (MEKK1S222A), Rho (N19RhoA), Rac (N17Rac), Cdc42 (N17Cdc42), SEK1 (SEK1-K/R), or PKCzeta (PKCzeta mut) does not disrupt the effect of p110* on promoter activity, indicating that these factors are not required to mediate the effect of PI3K on the IGFBP-1 promoter.

We next asked whether PKB/Akt may mediate PI3K-dependent effects of insulin on the IGFBP-1 promoter. Western blotting and in vitro kinase studies demonstrate that PKB/Akt is expressed in HepG2 cells and activated by insulin(Fig. 3A). This effect of insulin is inhibited by LY294002, but not by rapamycin (Fig. 3A), consistent with previous studies regarding the activation of PKB/Akt (7).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 3.   Role of PKB/Akt in the regulation of the IGFBP-1 promoter. A, detection and activation of endogenous PKB/Akt. HepG2 cells were stabilized in DMEM/BSA, then treated with 50 µM LY294002 (LY) or 200 nM rapamycin (Rapa) for 30 min prior to the addition of insulin or buffer alone. Cell lysates were prepared 10 min later in the presence of protease and phosphatase inhibitors. PKB/Akt was precipitated with specific anti-Akt antibodies and prepared for 8% SDS-PAGE and Western blotting (top panel) or for in vitro kinase assay using histone 2B as a substrate (lower panel). B, effect of constitutively active PKB/Akt on promoter activity. HepG2 cells were transfected with 10 µg of DNA/dish, including 3 µg of BP1.luc, 2 µg of beta -gal vector, and 0.1, 1, or 5 µg of Myr-PKB/Akt (Myr-PKB) plus 0-5 µg of empty vector. To examine for additive effects, cells were co-transfected with 1 µg of Myr-PKB or p110* and treated with insulin (INS) or buffer alone as indicated. C, effect of K179 PKB/Akt. To examine effects of K179 PKB/Akt on promoter activity (top panel), HepG2 cells were transfected with a total of 15 µg of DNA/dish, including 2 µg of BP1.luc, 2 µg of beta -gal vector plus 1 µg of p110*, 1 µg of Myr-PKB/Akt, and 10 µg of K179 PKB/Akt or 0-11 µg of empty vector and treated with insulin (INS) or buffer alone, as indicated. To examine for effects of K179 on the activation of PKB/Akt, cells were transfected with 12 µg of DNA/dish, including 1 µg of HA-tagged wild type PKB/Akt, 1 µg of HA-tagged Myr-PKB/Akt, 1 µg of p110*, 10 µg of K179 PKB/Akt, and 10-11 µg of empty vector, then treated with 100 nM insulin or buffer alone for 10 min as indicated. Lysates were prepared in the presence of protease and phosphatase inhibitors and HA-tagged proteins precipitated for in vitro kinase assay (middle panel) or Western blotting (bottom panel), as described under "Materials and Methods."

To determine whether PKB/Akt is sufficient to mediate effects of insulin and/or PI3K on promoter activity, we next performed studies with constitutively active PKB/Akt (Myr-PKB/Akt). As shown in Fig. 3B, Myr-PKB/Akt inhibits IGFBP-1 promoter activity in a dose-dependent fashion. This effect of Myr-PKB/Akt is not additive with the effect of either insulin or p110* (Fig. 3B), indicating that the effects of insulin and PI3K on IGFBP-1 promoter activity may be mediated through PKB/Akt. In separate experiments, 18-h conditioned medium collected from Myr-PKB/Akt- or p110*-transfected cells had no effect on IGFBP-1 promoter activity (data not shown), indicating that the effects of PKB/Akt and PI3K on promoter activity are due to stimulation of intracellular pathways and not the generation of autocrine factors.

We next performed studies with the dominant negative K179 mutant of PKB/Akt (8). Initial dose-response studies showed that increasing amounts of the K179 PKB/Akt progressively block the effects of both insulin and p110* on IGFBP-1 promoter activity (not shown). As shown in Fig. 3C, K179 PKB/Akt disrupts the effects of insulin and PI3K on promoter activity without blocking the ability of Myr-PKB/Akt to signal downstream and inhibit the activity of the IGFBP-1 promoter. In vitro kinase assays and Western blotting reveal that K179 PKB/Akt prevents the activation of HA-tagged wild type PKB/Akt by insulin and p110* without altering protein levels or disrupting the activity of Myr-PKB/Akt (Fig. 3C). These results indicate that insulin and PI3K act upstream of PKB/Akt and activation of PKB/Akt is required to mediate effects of insulin and PI3K on the IGFBP-1 promoter.

We next asked whether PI3K and PKB/Akt mediate their effects on promoter activity in a sequence-specific fashion through an IRS. As shown in Table I, the creation of an NheI site just 5' from IRSA (CAAAACAA) (BP1.Nhe) does not disrupt the inhibitory effect of insulin, p110*, or Myr-PKB/Akt on promoter activity. Mutation (mIRS) or deletion (Delta IRS) of both IRSs completely disrupts the ability of insulin, p110*, and Myr-PKB/Akt to inhibit basal IGFBP-1 promoter activity. Restoring either IRSA (Delta IRS.A) or IRSB (TTATTTTG) (Delta IRS.B) is sufficient to confer the effect of insulin, p110*, and Myr-PKB/Akt on the IGFBP-1 promoter. Mutation of a single bp in either IRSA (Delta IRS.Amut) or IRSB (Delta IRS.Bmut) completely disrupts the effects of insulin, p110*, and Myr-PKB/Akt, demonstrating that these effects are sequence-specific. Placement of highly related IRSs identified in the PEPCK (CAAAACAC; Delta IRS.PEPCK) or apoCIII (CCAAACAT; Delta IRS.apoCIII) genes in the site of IRSA also confers the effect of insulin, p110*, and Myr-PKB/Akt on promoter activity. Placement of IRSA at a different site, 331 bp 5' to the RNA cap site (Delta IRS.331.A), also fully restores the effects of insulin, p110*, and Myr-PKB/Akt on promoter activity, while insertion of a mutated IRS at this location (Delta IRS.331.Amut) is not effective. Taken together, these results indicate that the effects of insulin, PI3K, and PKB/Akt are all mediated through IRSs in a sequence-specific fashion and that highly related IRSs from other hepatic genes also can mediate the effects of insulin, PI3K, and PKB/Akt on basal promoter activity in liver-derived cells.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Sequence-specific effects of insulin, PI3K, and PKB/Akt on IGFBP-1 promoter activity in HepG2 cells
Creation of an NheI site (GCTAGC) 5' to IRSA (CAAAACAA) by site-directed mutagenesis of 2 bp (BP1.Nhe) does not disrupt the effect of insulin, p110*, or Myr-PKB/Akt on promoter activity. A BamHI site (GGATCC) is located 3' to IRSB (TTATTTTG). To create modified IRSs, the NheI-BamHI fragment was excised and replaced with synthetic double-stranded oligonucleotides. IRSA with/without mutation also was inserted into the SmaI/MluI site in the pGL2 polylinker just upstream from the 5' end of the Delta IRS promoter. HepG2 cells were transfected with 10 µg of DNA/dish, including 3 µg of reporter gene construct, 2 µg of beta -gal vector plus 1 µg of p110* or 1 µg of Myr-PKB/Akt, and 4-5 µg of empty vector, and treated with insulin or buffer alone prior to harvest and analysis of luciferase and beta -galactosidase activity.

These results provide the first report demonstrating that PKB/Akt exerts sequence-specific effects on gene expression and mediates the effect of insulin on basal hepatic gene expression through a conserved IRS. Early studies with cycloheximide revealed that insulin inhibits IGFBP-1 and PEPCK transcription through post-translational modification of pre-existing factors (41, 42). Meier et al. (43) recently reported that activated forms of protein kinase B are translocated to the nucleus where they may interact with and modify the activity of nuclear factors involved in the regulation of gene expression. Phosphorylation and inactivation of glycogen synthase kinase-3 (11), which is present in the nucleus and known to phosphorylate several transcription factors (44, 45), may provide one mechanism by which PKB/Akt may alter gene expression. We previously reported that members of the HNF-3/forkhead family of transcription factors interact with IRSs in both the IGFBP-1 and PEPCK promoter (35, 46). Subsequent studies in other laboratories have confirmed this result (47, 48) and demonstrated that HNF-3/forkhead proteins also interact with the apoCIII IRS (48). An insulin-responsive sequence in the tyrosine aminotransferase gene also binds HNF-3/forkhead proteins (49). Additional studies are required to determine whether post-translational modification of HNF-3/forkhead proteins or other specific trans-acting factors mediate effects of insulin on hepatic gene expression downstream from PKB/Akt.

Based on these results, we suggest that, in addition to mediating effects of insulin on carbohydrate metabolism in peripheral tissues (5, 6, 50), PKB/Akt also plays a critical role in mediating effects of insulin on hepatic gene expression through a conserved IRS. Krook et al. (51) reported that the activation of PKB/Akt by insulin is impaired in skeletal muscle in insulin-resistant diabetic rats. Bang et al. (52) reported that circulating levels of IGFBP-1 are not appropriately suppressed in insulin-resistant patients with Type 2 diabetes and suggested that these individuals may be resistant to the effect of insulin on hepatic production of IGFBP-1. It remains to be determined whether defects in signaling through the PI3K-PKB/Akt-IRS pathway impair the ability of insulin to regulate hepatic function and contribute to the pathogenesis of some forms of diabetes mellitus.

    ACKNOWLEDGEMENTS

We gratefully acknowledge Melissa Schroeder for her technical assistance and Drs. Richard Roth, Thomas Franke, and Nissim Hay for their helpful discussions and suggestions.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant DK41430 (to T. G. U.) and by the Department of Veterans Affairs Merit Review Program (to T. G. U.). This research was presented in part at the 79th Annual Meeting of the Endocrine Society, June 14, 1997, Minneapolis, MN.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

These authors contributed equally to this work.

** To whom all correspondence should be addressed: Rm. 5A122A Research (M.P. 151), Veterans Affairs Chicago Area Health Care System, West Side Division, 820 South Damen Ave., Chicago, IL 60612. Tel.: 312-666-6500 (ext. 3427); Fax: 312-455-5877; E-mail: unterman{at}uic.edu.

1 The abbreviations used are: PI3K, phosphatidylinositol 3'-kinase; IRS, insulin response element; IGFBP-1, insulin-like growth factor-binding protein-1; PEPCK, phosphoenolpyruvate carboxykinase; apoCIII, apolipoprotein CIII; PKB, protein kinase B; PKA, protein kinase A; PKC, protein kinase C; HA, hemagglutinin; Myr, myristoylated; DMEM, Dulbecco's modified Eagle's medium; BCS, bovine calf serum; BSA, bovine serum albumin; beta -gal, beta -galactosidase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References

  1. Cheatham, B., and Kahn, C. R. (1995) Endocr. Rev 16, 117-142[Medline] [Order article via Infotrieve]
  2. Martin, S. S., Haruta, T., Morris, A. J., Klippel, A., Williams, L. T., Olefsky, J. M. (1996) J. Biol. Chem. 271, 17605-17608[Abstract/Free Full Text]
  3. Cheatham, B., Vlahos, C. J., Cheatham, L., Wang, L., Blenis, J., and Kahn, C. R. (1994) Mol. Cell. Biol. 14, 4902-4911[Abstract]
  4. Price, D. J., Grove, J. R., Calvo, V., Avruch, J., and Bierer, B. E. (1992) Science 257, 973-977[Medline] [Order article via Infotrieve]
  5. Osawa, H., Sutherland, C., Robey, R. B., Printz, R. L., Granner, D. K. (1996) J. Biol. Chem. 271, 16690-16694[Abstract/Free Full Text]
  6. Bellacosa, A., Franke, T. F., Gonzalez-Portal, E., Data, K., Taguchi, R. T., Gardner, J., Cheng, J. Q., Testa, J. R., Tsichlis, P. N. (1993) Oncogene 8, 745-754[Medline] [Order article via Infotrieve]
  7. Burgering, B. M. T., and Coffer, P. J. (1995) Nature 376, 599-602[CrossRef][Medline] [Order article via Infotrieve]
  8. Songyang, Z., Baltimore, D., Cantley, L. C., Kaplan, D. R., Franke, T. F. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 11345-11350[Abstract/Free Full Text]
  9. Hemmings, B. A. (1997) Science 275, 628-630[Free Full Text]
  10. Kennedy, S. G., Wagner, A. J., Couzen, S. D., Jordan, J., Bellacosa, A., Tsichlis, P. N., Hay, N. (1997) Genes Dev. 11, 701-703[Abstract]
  11. Cross, D., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. (1995) Nature 378, 785-789[CrossRef][Medline] [Order article via Infotrieve]
  12. Kohn, A. D., Summers, S. A., Birnbaum, M. J., Roth, R. A. (1996) J. Biol. Chem. 271, 31372-31378[Abstract/Free Full Text]
  13. O'Brien, R. M., and Granner, D. K. (1996) Physiol. Rev. 76, 1109-1161[Abstract/Free Full Text]
  14. Unterman, T. G., Oehler, D. T., Murphy, L. J., Lacson, R. G. (1991) Endocrinology 128, 2693-2701[Abstract]
  15. Powell, D. R., Suwanichkul, A., Cubbage, M. L., DePaolis, L. A., Snuggs, M. B., Lee, P. D. K. (1991) J. Biol. Chem. 266, 18868-18876[Abstract/Free Full Text]
  16. Orlowski, C. C., Ooi, G. T., Brown, D. R., Yang, Y. W.-H., Tseng, L. Y.-H., Rechler, M. M. (1991) Mol. Endocrinol. 5, 1180-1187[Abstract]
  17. Goswami, R., Lacson, R., Yang, E., Sam, R., and And Unterman, T. (1994) Endocrinology 134, 2531-2539
  18. Suwanichkul, A., Morris, S. L., and Powell, D. R. (1993) J. Biol. Chem. 268, 17063-17068[Abstract/Free Full Text]
  19. Unterman, T. G., Oehler, D. T., Nguyen, H., Sengupta, P., and Lacson, R. G. (1995) Prog. Growth Factor Res. 6, 119-129[CrossRef][Medline] [Order article via Infotrieve]
  20. O'Brien, R. M., Lucas, P. C., Forest, C. D., Magnuson, M. A., Granner, D. K. (1990) Science 249, 533-537[Medline] [Order article via Infotrieve]
  21. Li, W. W., Dammerman, M. M., Smith, J. D., Metzger, S., Breslow, J. L., Leff, T. (1995) J. Clin. Invest. 96, 2601-2605[Medline] [Order article via Infotrieve]
  22. Sutherland, C., O'Brien, R. M., and Granner, D. K. (1995) J. Biol. Chem. 270, 15501-15506[Abstract/Free Full Text]
  23. Band, C. J., and Posner, B. I. (1997) J. Biol. Chem. 272, 138-145[Abstract/Free Full Text]
  24. Quinn, P. G. (1994) J. Biol. Chem. 269, 14375-14378[Abstract/Free Full Text]
  25. Nakajima, T., Fukamizu, A., Takahashi, J., Gage, F. H., Fisher, T., Blenis, J., Montminy, M. R. (1996) Cell 86, 465-474[Medline] [Order article via Infotrieve]
  26. Brewer, M. T., Stetlet, G. L., Squires, C. H., Thompson, R. C., Busby, W. H., Clemmons, D. R. (1998) Biochem. Biophys. Res. Commun. 152, 1289-1297
  27. Hara, K., Yonezawa, K., Sakue, H., Ando, A., Kotani, K., Kitmura, Y., Ueda, H., Stephens, L., Jackson, T. R., Hawkins, P. T., Dhand, R., Clark, A. E., Holman, G. D., Waterfield, M. D., Kasuga, M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7415-7419[Abstract]
  28. Kohn, A. D., Kovacina, K. S., and Roth, R. D. (1995) EMBO J. 14, 4288-4295[Abstract]
  29. Feig, L. A., and Cooper, G. M. (1988) Mol. Cell. Biol. 8, 3235-3243[Medline] [Order article via Infotrieve]
  30. Bruder, J. T., Heidecker, G., and Rapp, U. R. (1992) Genes Dev. 6, 545-556[Abstract]
  31. Seger, R., Sager, D., Rescue, A. A., Manner, E. S. P., Elder-Finkelman, H., Dobrowolska, G., Jensen, A. M., Campbell, J. S., Fischer, E. H., Krebs, E. G. (1994) J. Biol. Chem. 41, 25699-25709
  32. Coso, O., Chiarello, M., Yu, J., Teramoto, H., Crespo, P., Xu, N., Miki, T., and Gutkind, J. S. (1995) Cell 81, 1137-1146[Medline] [Order article via Infotrieve]
  33. Sanchez, I., Hughes, R. T., Mayer, B. J., Yee, K., Woodgett, J. R., Avruch, J., Kyriakis, J. M., Zon, L. I. (1994) Nature 372, 794-797[Medline] [Order article via Infotrieve]
  34. Daiz-Meco, M. T., Lozano, J., Municio, M. M., Berra, E., Frutos, S., Sanz, L., Moscat, J. (1994) J. Biol. Chem. 269, 31706-31710[Abstract/Free Full Text]
  35. Unterman, T. G., Fareeduddin, A., Harris, M. A., Goswami, R. G., Porcella, A., Costa, R., Lacson, R. (1994) Biochem. Biophys. Res. Commun. 203, 1835-1841[CrossRef][Medline] [Order article via Infotrieve]
  36. Hu, Q., Klippel, A., Muslin, A. J., Fantl, W. J., William, L. T. (1995) Science 268, 100-102[Medline] [Order article via Infotrieve]
  37. Klippel, A., Escobedo, J. A., Hu, Q., and Williams, L. T. (1993) Mol. Cell. Biol. 16, 4117-4127[Abstract]
  38. Yamauchi, K., Holt, K., and Pessin, J. E. (1993) J. Biol. Chem. 268, 14597-14600[Abstract/Free Full Text]
  39. Kotani, K., Hara, K., Yonezawa, K., and Kasuga, M. (1995) Biochem. Biophys. Res. Commun. 208, 985-990[CrossRef][Medline] [Order article via Infotrieve]
  40. Standaert, M. L., Galloway, L., Purushotham, K., Bandyopadhyay, G., Moscat, J., and Farese, R. V. (1997) J. Biol. Chem. 272, 30075-30082[Abstract/Free Full Text]
  41. Ooi, G. T., Brown, D. R., Suh, D. S., Tseng, L. Y.-H., Rechler, M. M. (1993) J. Biol. Chem. 268, 16664-16672[Abstract/Free Full Text]
  42. Sasaki, K., Cripe, T. P., Koch, S. R., Andreone, T. L., Peterson, D. D., Beale, E. G., Granner, D. K. (1984) J. Biol. Chem. 259, 15242-15251[Abstract/Free Full Text]
  43. Meier, R., Alessi, D. R., Cron, P., Andjelkovic', M., and Hemmings, B. A. (1997) J. Biol. Chem. 272, 30491-30497[Abstract/Free Full Text]
  44. Marte, B. M., and Downward, J. (1997) Trends Biochem. Sci. 22, 355-358[CrossRef][Medline] [Order article via Infotrieve]
  45. Beals, C. R., Sheridan, C. M., Turck, C. W., Gardner, P., Crabtree, G. (1997) Science 275, 1930-1933[Abstract/Free Full Text]
  46. Unterman, T., Costa, R., and Lacson, R. (1994) Clin. Res. 42, 213A
  47. O'Brien, R. M., Noisin, E. L., Suwanickul, A., Yamamsaki, T., Lucas, P. C., Wang, J.-C., Granner, D. K. (1995) Mol. Cell. Biol. 15, 1747-1758[Abstract]
  48. Powell, D. R., Allander, S. V., Scheimann, A. O., Wasserman, R. M., Durham, S. K., Suwanichkul, A. (1995) Prog. Growth Factor Res. 6, 93-101[Medline] [Order article via Infotrieve]
  49. Ganss, R., Weih, F., and Schütz, G. (1994) Mol. Endocrinol. 8, 895-903[Abstract]
  50. Tanti, J. F., Grillo, S., Gremeaux, T., Coffer, P. J., Van Obberghen, E., Le Marchand-Brustel, Y. (1997) Endocrinology 138, 2005-2010[Abstract/Free Full Text]
  51. Krook, A., Kawano, Y., Song, X. M., Efendic, S., Roth, R. A., Wallberg-Henriksson, H., Zierath, J. R. (1997) Diabetes 46, 2110-2114[Abstract]
  52. Bang, P., Brismar, K., Rosenfeld, R. G., Hall, K. (1994) J. Clin. Endocrinol. & Metab. 78, 960-967[Abstract]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.